Pfizer Inc. and partner BioNTech SE have said their COVID-19 vaccine was safe and produced strong antibody responses in children age 5 to 11 in a large-scale trial, findings that could pave the way for the start of vaccinations for grade-school kids within months.
The long-awaited results offer one of the first looks at how well a COVID-19 vaccine could work for younger children. Pressure to immunize kids has been on the climb in the U.S., where a new school year has started just as the delta variant is fueling a surge in cases.
In a trial with 2,268 participants, two shots of a 10 microgram dose — one-third of the adult shot — produced antibody levels comparable to those seen in a trial of 16- to 25-year-olds who got the adult dose, the companies said, with similar side effects.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.